First Alzheimer's Drug Authorised In Switzerland

2026-02-04 02:12:06

(MENAFN- Swissinfo) The Swiss medicines regulator Swissmedic has for the first time authorised a drug (Donanemab) that can slow down the progression of Alzheimer's disease. Select your language

Generated with artificial intelligence. Listening: First Alzheimer's drug authorised in Switzerland This content was published on February 4, 2026 - 16:23 2 minutes Keystone-SDA

Deutsch de Erstes Alzheimermedikament ist in der Schweiz zugelassen Original Read more: Erstes Alzheimermedikament ist in der Schweiz zugel

+Get the most important news from Switzerland in your inbox

Swissmedic rates the benefits of the active substance higher than possible side effects. In a joint press release with Swiss Memory Clinics, Alzheimer Switzerland welcomed the authorisation.

+ Swiss regulators weigh hope and hype with new Alzheimer's drugs

The antibody Donanemab, developed by Eli Lilly under the trade name Kisunla, reduces protein deposits in the brain. It is intended for patients in the early stages of the disease and is designed to delay cognitive decline.

However, the treatment also has potential risks such as brain swelling or bleeding and requires careful monitoring.

It is still unclear whether the costs will be covered by health insurance companies.
More More New treatments Science podcast: cracking the Alzheimer's code
This content was published on Jan 16, 2026 In episode 2 of the Swiss Connection science podcast, we explore the latest treatments for Alzheimer's disease.
Read more: Science podcast: cracking the Alzheimer's

MENAFN04022026000210011054ID1110696308

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.